Glycosaminoglycan and proteoglycan inhibit the depolymerization of β2-microglobulin amyloid fibrils in vitro

Kidney International

Volumn 64, Issue 3, 2003, Pages 1080-1088

  Yamaguchi, Itaru ^b   Suda, Hironori ^b   Tsuzuike, Naoki ^b   Seto, Kouichi ^b   Seki, Masaharu ^b   Yamaguchi, Yukiya ^b   Hasegawa, Kazuhiro ^b   Takahashi, Naoki ^b   Yamamoto, Suguru ^b   Gejyo, Fumitake ^b   Naiki, Hironobu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NONE

Author keywords

Amyloidosis; Murine; Proteoglycan

Indexed keywords

AMYLOID; BETA 2 MICROGLOBULIN; BIGLYCAN; DECORIN; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; KERATAN SULFATE; PROTEOGLYCAN; THIOFLAVINE;

ACIDITY; AMYLOIDOSIS; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CELL SURFACE; CONCENTRATION RESPONSE; DEPOLYMERIZATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INHIBITION KINETICS; KIDNEY AMYLOIDOSIS; MOLECULAR DYNAMICS; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN POLYMERIZATION; PROTEIN STABILITY; REACTION ANALYSIS; TEMPERATURE DEPENDENCE;

EID: 12444276291     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00167.x     Document Type: Article

References (58)

1. KOCH KM: Dialysis-related amyloidosis. Kidney Int 41:1416-1429, 1992
2. CHARRA B, CALEMARD E, UZAN M, et al: Carpal tunnel syndrome, shoulder pain and amyloid deposition in long-term hemodialysis patients. Proc Eur Dial Transplant Assoc 21:291-295, 1984
3. GEJYO F, ARAKAWA M: Dialysis amyloidosis: Current disease concepts and new perspectives for its treatment. Contrib Nephrol 78:47-60, 1990
4. 2-microglobulin. Biochem Biophys Res Commun 129:701-706, 1985
5. 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci USA 83:7908-7912, 1986
6. 2-microglobulin amyloid fibrils in peripheral blood mononuclear cell culture. Am J Pathol 141:241-247, 1992
7. 2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis. Kidney Int 50:1262-1267, 1996
8. CHANARD J, BINDI P, LAVAUD S, et al: Carpal tunnel syndrome and type of dialysis membrane. Br Med J 298:867-868, 1989
9. VAN YPERSELE DE STRIHOU C, JADOUL M, MALGHEM J, et al: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 39:1012-1019, 1991
10. 2-Microglobulin and amyloidosis: Who is at risk? Nephrol Dial Transplant 10(Suppl 10):48-51, 1995
11. NAIKI H, HIGUCHI K, NAKAKUKI K, TAKEDA T: Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 65:104-110, 1991
12. JARRETT JT, LANSBURY PT, JR: Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058, 1993
13. NAIKI H, NAKAKUKI K: First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab Invest 74:374-383, 1996
14. NAIKI H, GEJYO F, NAKAKUKI K: Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro. Biochemistry 36:6243-6250, 1997
15. NAIKI H, HASHIMOTO N, SUZUKI S, et al: Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro. Amyloid 4:223-232, 1997
16. 2-Microglobulin and its deamidated variant, N17D form amyloid fibrils with a range of morphologies in vitro. J Mol Biol 313:559-571, 2001
17. XING Y, NAKAMURA A, CHIBA T, et al: Transmission of mouse senile amyloidosis. Lab Invest 81:493-499, 2001
18. LUNDMARK K, WESTERMARK GT, NYSTROM S, et al: Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 99:6979-6984, 2002
19. 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 40:8499-8507, 2001
20. 2-microglobulin amyloid fibril by H/D exchange. Nat Struct Biol 9:332-336, 2002
21. CHITI F, DE LORENZI E, GROSSI S, et al: A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J Biol Chem 276:46714-46721, 2001
22. OHISHI H, SKINNER M, SATO-ARAKI N, et al: Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen. Clin Chem 36:88-91, 1990
23. 2-microglobulin amyloid deposits. Kidney Int 42:915-923, 1992
24. OHASHI K, HARA M, YANAGISHITA M, et al: Proteoglycans in haemodialysis-related amyloidosis. Virchows Arch 427:49-59, 1995
25. 2-microglobulin amyloidosis: A comparative study with systemic AA and AL amyloidosis. Virchows Arch 430:479-487, 1997
26. 2-microglobulin amyloid fibrils. Kidney Int 52:1543-1549, 1997
27. 2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41:1646-1652, 1992
28. 2-microglobulin amyloidosis and clues for its histogenesis. Kidney Int 55:1983-1990, 1999
29. HARDINGHAM TE, FOSANG AJ: Proteoglycans: Many forms and many functions. FASEB J 6:861-870, 1992
30. ROSENBERG LC, CHOI HU, TANG LH, et al: Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J Biol Chem 260:6304-6313, 1985
31. FISHER LW, HAWKINS GR, TUROSS N, TERMINE JD: Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, andosteonectin from the mineral compartment of developing human bone. J Biol Chem 262:9702-9708, 1987
32. POGÁNY G, HERNANDEZ DJ, VOGEL KG: The in vitro interaction of proteoglycans with type I collagen is modulated by phosphate. Arch Biochem Biophys 313:102-111, 1994
33. ANCSIN JB, KISILEVSKY R: The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274:7172-7181, 1999
34. MCCUBBIN WD, KAY CM, NARINDRASORASAK S, KISILEVSKY R: Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 256:775-783, 1988
35. SNOW AD, BRAMSON R, MAR H, et al: A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 39:1321-1330, 1991
36. CASTILLO GM, CUMMINGS JA, YANG W, et al: Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47:612-620, 1998
37. MCLAURIN J, FRANKLIN T, ZHANG X, et al: Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans: Effects on fibril nucleation and growth. Eur J Biochem 266:1101-1110, 1999
38. CASTILLO GM, NGO C, CUMMINGS J, et al: Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem 69:2452-2465, 1997
39. 2-microglobulin. Amyloid 8:30-40, 2001
40. MCLAURIN J, FRASER PE: Effect of amino-acid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions. Eur J Biochem 267:6353-6361, 2000
41. 2-microglobulin. Nephron 90:158-168, 2002
42. IOZZO RV: The family of the small leucine-rich proteoglycans: Key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32:141-174, 1997
43. IOZZO RV: Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 67:609-652, 1998
44. SCHONHERR E, WITSCH-PREHM P, HARRACH B, et al: Interaction of biglycan with type I collagen. J Biol Chem 270:2776-2783, 1995
45. YAMAGUCHI Y, MANN DM, RUOSLAHTI E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 346:281-284, 1990
46. HOCKING AM, STRUGNELL RA, RAMAMURTHY P, MCQUILLAN DJ: Eukaryotic expression of recombinant biglycan: Post-translational processing and the importance of secondary structure for biological activity. J Biol Chem 271:19571-19577, 1996
47. KRUMDIECK R, HÖÖK M, ROSENBERG LC, VOLANAKIS JE: The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol 149:3695-3701, 1992
48. GUPTA-BANSAL R, FREDERICKSON RC, BRUNDEN KR: Proteoglycan-mediated inhibition of Aβ proteolysis: A potential cause of senile plaque accumulation. J Biol Chem 270:18666-18671, 1995
49. LOMAKIN A, TEPLOW DB, KIRSCHNER DA, BENEDEK GB: Kinetic theory of fibrillogenesis of amyloid β-protein. Proc Natl Acad Sci USA 94:7942-7947, 1997
50. FRASER PE, DARABIE AA, MCLAURIN JA: Amyloid-β interactions with chondroitin sulfate-derived monosaccharides and disaccharides: Implications for drug development. J Biol Chem 276:6412-6419, 2001
51. 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314:585-586, 1986
52. ROUGHLEY PJ, WHITE RJ, MAGNY MC, et al: Non-proteoglycan forms of biglycan increase with age in human articular cartilage. Biochem J 295:421-426, 1993
53. ROUGHLEY PJ, MELCHING LI, RECKLIES AD: Changes in the expression of decorin and biglycan in human articular cartilage with age and regulation by TGF-β. Matrix Biol 14:51-59, 1994
54. SZTROLOVICS R, ALINI M, MORT JS, ROUGHLEY PJ: Age-related changes in fibromodulin and lumican in human intervertebral discs. Spine 24:1765-1771, 1999
55. MCALINDEN A, DUDHIA J, BOLTON MC, et al: Age-related changes in the synthesis and mRNA expression of decorin and aggrecan in human meniscus and articular cartilage. Osteoarthritis Cartilage 9:33-41, 2001
56. JADOUL M, GARBAR C, VANHOLDER R, et al: Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 54:956-959, 1998
57. KISILEVSKY R, LEMIEUX LJ, FRASER PE, et al: Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat Med 1:143-148, 1995
58. KISILEVSKY R, SZAREK WA: Novel glycosaminoglycan precursors as anti-amyloid agents part II. J Mol Neurosci 19:45-50, 2002